BBOT BridgeBio Oncology Therapeutics Inc.
USHealthcareAs of 2026-07-10 15:37
Why BBOT matters now
BridgeBio Oncology Therapeutics Inc. (BBOT) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.35 with -8.14% on the session and $668.9M in market capitalization; recent performance reads 1-month -13.30% and YTD -39.62%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-42.1M, and EPS of $-1.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.6%.
The latest indexable market news headline is "BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.00; recent insider activity includes Kumar Neil filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.63
P/S
0.00
EV/EBITDA
-3.30
DCF Value
$11.88
FCF Yield
-28.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.5%
ROA
-36.9%
ROIC
-45.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-42.1M | $-1.35 |
| Q4 2025 | $0.00 | $-38.8M | $-1.25 |
| FY 2025 | $0.00 | $-134.0M | $-4.30 |
| Q3 2025 | $0.00 | $-44.8M | $-1.90 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.00
Target (Median)
$23.00
Target Range
$18.00 - $24.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.29
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.